What Arquitos does

Arquitos Capital Management, LLC is a privately-held hedge fund management firm founded in 2012 and headquartered in New York. The firm operates two distinct investment vehicles targeting concentrated, high-conviction opportunities for high-net-worth individual investors. Arquitos Capital, the primary fund, invests in pre-revenue biotechnology companies trading materially below their net cash value following failed Phase 3 clinical trials, exploiting the dislocation between residual cash assets and depressed equity prices. Arquitos Epicus, launched in 2022, pursues event-driven, catalyst-driven opportunities — including restructurings, regulatory catalysts, activism, spin-offs, and divestitures — targeting 5x-10x returns on individual positions.

The firm reports a 13.6% annualized net return since inception. Notable portfolio holdings disclosed include ENDI Corp (described with $21.3M in revenue and 38% growth) and Liquidia Corporation / Yutrepia (projected by the firm to reach $1.2B in 2027), reflecting the high-conviction, low-name-count portfolio construction typical of the strategy. In Q1 2026 the firm returned -7.2% net-of-fees, underperforming the Russell 2000's +0.9%, a result that raises near-term capital retention considerations. Arquitos generates revenue through standard hedge fund economics: asset-based management fees on committed capital combined with performance-based incentive fees on fund returns, although no AUM, fee schedule, or financial figures are publicly disclosed.

Arquitos operates without proprietary technology, quantitative infrastructure, or AI capabilities, with investment decisions driven by fundamental analysis conducted by a four-person team: Jakob Fleischmann (CIO), Yaniv Davidson (CEO), Benjamin Hider (COO), and Sean Coleman (Senior Analyst). Distribution is conducted via direct investor relationships, with Arquitos Epicus operating on a referral and waitlist basis — all spots currently reserved for existing relationships, with periodic openings offered to new investors.

Name

Arquitos

Legal name

Arquitos Capital Management, LLC

Website

https://arquitos.com

Company type

Private

Founded year

2012

Operating status

Operating

Short description

Arquitos Capital Management is a privately-held New York-based hedge fund founded in 2012 that runs two concentrated vehicles: a primary fund targeting pre-revenue biotech companies trading below net cash, and Arquitos Epicus, an event-driven fund, both serving high-net-worth individual investors via direct relationships.

Ownership category

akta.pro rank

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Hedge Fund Management: Arquitos Capital generates revenue through hedge fund management fees and performance-based compensation. As a registered investment adviser, they manage capital for qualified investors seeking long-term value creation through concentrated positions in unique investment opportunities.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Arquitos Capital is a hedge fund management firm that runs concentrated, long-term investment portfolios for qualified investors, specializing in pre-revenue biotech companies trading below net cash value following failed Phase 3 clinical trials. In 2022 it launched a complementary fund, Arquitos Epicus, that pursues higher-risk, event-driven, catalyst-driven opportunities targeting 5x to 10x returns through regulatory issues, restructurings, activism, spin-offs, and divestitures.

Product overview

Arquitos Capital operates as an unconventional hedge fund with a concentrated portfolio approach, offering two distinct investment products: the primary Arquitos Capital fund targeting undervalued pre-revenue biotech companies trading below net cash following failed clinical trials, and the complementary Arquitos Epicus fund (launched in 2022) focusing on high-concentration, event-driven opportunities seeking 5x to 10x returns.

Differentiator

Problem solved

Functional benefit

Brands

• Arquitos Epicus: A complementary fund launched in 2022 that provides opportunities for more risk through investments in multi-bagger, event and catalyst-driven opportunities. Makes highly concentrated investments in asymmetric event-driven opportunities targeting 5x to 10x opportunities in companies going through regulatory issues, restructurings, activism, spin-offs, divestitures, and other company and event-specific issues.

Products and services

• Arquitos Capital (Primary Fund) The primary Arquitos Capital hedge fund, a concentrated, long-term investment vehicle for qualified investors that invests in a small number of unique companies with a specialized focus on pre-revenue biotech companies trading significantly below their net cash value following failed Phase 3 clinical trials.
• Arquitos Epicus A complementary fund launched in 2022 that makes highly concentrated, event-driven, catalyst-driven investments targeting 5x to 10x returns in companies going through regulatory issues, restructurings, activism, spin-offs, divestitures, and other company- or event-specific situations; typically allocated via approximately 20% in equity, warrants, and/or options.

Quantifiable outcome

• 13.6% annualized returns since inception
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves4 records

Expansion highlights2 records

Direct peers

• Avoro Capital (formerly venBio): Biotech-only fund pursuing large, concentrated positions in clinical-stage therapeutics; aligns closely with Arquitos' under-the-radar biotech thesis and willingness to underwrite clinical and regulatory risk.
• Baker Brothers Advisors: Long-running, biotech-specialist hedge fund with a fundamentally driven, concentrated approach to mispriced healthcare equities - directly comparable to Arquitos' deep biotech bench and contrarian, cash-anchored valuation style.
• OrbiMed Advisors: Healthcare-dedicated investment platform spanning long/short equities, venture, and royalty/credit; overlapping with both Arquitos funds in biotech concentration and event-driven opportunity selection.
• Sectoral Asset Management: Healthcare-specialist long/short equity manager concentrated in global biotech and pharma; comparable to Arquitos' sector focus and concentrated-position style.
• BVF Partners (Bio-Value Fund): Value-oriented biotech hedge fund with a long track record of concentrated small/mid-cap biotech positions; highly comparable to Arquitos' pre-revenue / deeply undervalued-biotech mandate and tolerance for clinical-stage volatility.
• Perceptive Advisors: Healthcare-focused alternative asset manager running long-biased and credit strategies; comparable to Arquitos' core mandate but with broader healthcare/healthcare-credit reach than Arquitos' biotech-only emphasis.
• RA Capital Management: Catalyst-driven healthcare/ biotech hedge fund that combines public-equity specialist funds with private venture activity; mirrors Arquitos' emphasis on event/catalyst-driven biotech outcomes and mispriced clinical-stage names.
• Sarissa Capital Management: Activist event-driven healthcare/biotech fund targeting mispriced names subject to regulatory issues, restructurings and spin-offs - exceptionally close overlap with Arquitos Epicus' stated playbook of regulatory, restructuring, activism and divestiture opportunities.
• EcoR1 Capital: Sector-focused biotech hedge fund investing across the clinical-development continuum; comparable to Arquitos' specialization in small-cap biotech where binary catalysts drive concentrated returns.

Broad incumbents

• Deerfield Management: Large, diversified healthcare investment firm spanning public equities, private venture, and structured finance; covers the same biotech universe as Arquitos but with much broader product breadth, scale, and institutional infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/arquitos-capital-management

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arquitos